We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Molecular Diagnostic Test Detects Three Respiratory Viruses Simultaneously

By Labmedica staff writers
Posted on 17 Jan 2008
A real-time, molecular diagnostic assay simultaneously detects and differentiates influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) from a single specimen.

Called the ProFlu+ assay, it uses real-time polymerase chain reaction (PCR) technology, is simple to use, and easily integrates into existing lab workflow. More...
Real-time technology provides distinct advantages over other molecular diagnostic techniques such as microbeads and microarrays because little hands-on time is required, risk of amplicon contamination is eliminated, equipment cost is relatively low, and inducement concerns are minimized.

The accuracy of the ProFlu+ assay was confirmed in a multi-site clinical study that compared results to traditional viral culture. A total of 826 patient samples were prospectively tested, and the assay demonstrated an overall clinical sensitivity and specificity of 98% and 83%, respectively. The decreased specificity was the result of the ProFlu+ assay detecting more positive samples than cultures. Further testing by genetic sequencing determined that 87 of the 103 samples that were positive by ProFlu+ but negative by culture were likely to have been true-positives

Prodesse, Inc., (Waukesha, WI, USA) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA; Rockville, MD, USA) to market the ProFlu+ assay.

"We are convinced that we made the right choice choosing real-time PCR as our core technology platform,” said Tom Shannon, CEO of Prodesse. "Laboratorians are telling us that the big box multiplex systems are cumbersome and more appropriate for epidemiological, not clinical, applications. ProFlu+ is the first in a lineup of real-time respiratory assays that we are in the process of clearing. All of these will use a common internal control so that a single nucleic acid extraction can be used with multiple assays. Our Pro hMPV+ for detection of human metapneumovirus is currently in clinical trials, and two additional products will shortly begin clinical trials: ProParaflu+, a multiplex assay for differentiating parainfluenza viruses and our first enteric product, ProGastro Cd for Clostridium difficile.

Prodesse focuses on the development, manufacture, and distribution of cost-effective, easy-to-use reagents for infectious disease agents.


Related Links:
Prodesse
U.S. Food and Drug Administration

Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The model estimated about a fivefold return in gastric cancer prevention benefits per unit invested, with cost-effectiveness maintained in higher-cost settings (Image credit: Adobe Stock)

H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention

Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.